Runben Biotechnology (SH:603193) Xin Lang Cai Jing·2025-09-08 00:32Core Viewpoint - The company reported a stable performance in the first half of 2025, with significant growth in the baby care segment and effective product expansion strategies [1][2][3]. Financial Performance - In H1 2025, the company achieved revenue of 895 million yuan, net profit attributable to shareholders of 188 million yuan, and net profit excluding non-recurring items of 177 million yuan, representing year-on-year growth of 20.31%, 4.16%, and 0.86% respectively [1]. - In Q2 2025, the company recorded revenue of 655 million yuan, net profit attributable to shareholders of 143 million yuan, and net profit excluding non-recurring items of 138 million yuan, with year-on-year changes of +13.46%, -0.85%, and -3.94% respectively [1]. Product Performance - The company’s product categories showed varied performance: mosquito repellent products generated 375 million yuan in revenue (+13.4% YoY), baby care products reached 405 million yuan (+38.7% YoY), while essential oils saw a decline to 92 million yuan (-14.6% YoY) [2]. - The company maintained a strong market share across major e-commerce platforms and expanded offline channels, including a new partnership with Sam's Club, leading to rapid growth in non-platform distribution [2]. Profitability and Cost Structure - The company’s gross margin stood at 58.0%, a decrease of 0.6 percentage points year-on-year. The sales, management, R&D, and financial expense ratios were 30.3%, 1.81%, 1.83%, and -0.4% respectively, with year-on-year changes of +1.5, -0.1, -0.2, and +2.4 percentage points [2]. - The decline in net profit margin to 20.9% represented a year-on-year decrease of 3.2 percentage points, attributed to increased marketing expenditures and changes in channel structure [2]. Strategic Initiatives - The company continues to enhance its product matrix, launching over 40 new or upgraded products in H1 2025, while focusing on core categories like baby care and mosquito repellent, and entering new segments such as children's sunscreen and youth skincare [3]. - Significant capital investments are being made in the "Runben Biotechnology R&D Production Base Project" and the "Runben Intelligent Manufacturing Future Factory Project," strengthening the integrated R&D and production capabilities for long-term growth [3]. Investment Outlook - As a leading player in the domestic mosquito repellent and baby care sectors, the company is expected to benefit from its strong brand recognition and integrated model, which creates a competitive edge [3]. - Despite short-term pressure on profit margins due to increased marketing investments, the company’s multi-category and all-channel strategy is anticipated to enhance market share and provide clear growth pathways [3]. - The profit forecast for 2025-2027 has been slightly adjusted to 330 million yuan, 420 million yuan, and 530 million yuan respectively, with corresponding PE ratios of 37, 28, and 23 times [3].